Clinical Trials Logo

Squamous Cell Carcinoma clinical trials

View clinical trials related to Squamous Cell Carcinoma.

Filter by:
  • Withdrawn  
  • Page 1 ·  Next »

NCT ID: NCT05729139 Withdrawn - Clinical trials for Squamous Cell Carcinoma

Cemiplimab/Peg-Interferon-α in Advanced CSCC

Start date: July 2023
Phase: Phase 1
Study type: Interventional

The primary purpose of this research study is to test the safety and possible harms of cemiplimab/peg-interferon-alpha, when it is given to participants at different dose levels. The researchers want to find out what effects (good and bad) cemiplimab/Peg-Interferon has on participants with advanced cutaneous squamous cell carcinoma (aCSCC) so that they can find the best dose to treat aCSCC and reduce side effects as much as possible.

NCT ID: NCT05535023 Withdrawn - Clinical trials for Head and Neck Cancer

Phase 2 Study of Neoadjuvant SAR444245 Plus Cemiplimab in HPV Related Oropharynx Squamous Cell Carcinoma

Start date: August 24, 2022
Phase: Phase 2
Study type: Interventional

To learn if SAR444245 given in combination with cemiplimab can help to kill cancer cells in patients with HPV-related oropharynx cancer who are scheduled to have surgery to remove the disease

NCT ID: NCT04099446 Withdrawn - Melanoma (Skin) Clinical Trials

A Non-Interventional Pilot Study to Explore the Skin Microbes in Skin Cancer

Start date: October 2019
Phase:
Study type: Observational

This study seeks to correlate microbial sequencing data from a punch biopsy in patients with skin cancer both melanoma and non-melanoma.

NCT ID: NCT03652233 Withdrawn - Clinical trials for Squamous Cell Carcinoma

Afatinib and Nivolumab as Treatment for Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck

Start date: November 2, 2018
Phase: Phase 1
Study type: Interventional

This phase I/Ib trial will assess the dose, safety and side effects of the combination of the cancer drugs afatinib (GILOTRIF®) and nivolumab (OPDIVO®) and to assess the anti-cancer effects of this combination of drugs when used to treat patients with advanced head and neck cancers that did not respond to previous treatments.

NCT ID: NCT02298595 Withdrawn - Clinical trials for Squamous Cell Carcinoma

Cetuximab, Cisplatin and BYL719 for HPV-Associated Oropharyngeal Squamous Cell Carcinoma

Start date: August 2016
Phase: Phase 1/Phase 2
Study type: Interventional

This study evaluates the combination of BYL719, cisplatin and cetuximab as induction chemotherapy prior to minimally-invasive transoral surgery (TORS or TLM) and selective lymph node dissection (SLND), followed by risk-adapted intensity-modulated radiation therapy (IMRT) in patients with transorally resectable, Stage III-IVa, HPV-associated oropharyngeal squamous cell carcinoma (OPSCC).

NCT ID: NCT01484769 Withdrawn - Clinical trials for Squamous Cell Carcinoma

Method Development and Assessment of the Effects of Tobacco Products on Oral Cavity Cells

H&N
Start date: July 2005
Phase: N/A
Study type: Observational

Collection of tissues for analysis from patients undergoing elective neck dissection. The hypothesis of the study is that specific genetic alterations occur in head and neck cancers that have spread to regional and/or distant sites, and these alterations can be identified from biopsy specimens to allow more accurate staging of tumor and better treatment planning.

NCT ID: NCT01148082 Withdrawn - Clinical trials for Squamous Cell Carcinoma

School Response to Families Who Have Children With Cancer

Start date: September 2010
Phase: N/A
Study type: Observational

The purpose of this research is to investigate school response to families who have children with cancer. It is anticipated that the results of this study will enhance the support that schools can give to the population of families who have a child with cancer. The study will involve the parents in these families, the principal and an educator in the school of the child with cancer. Measurement tools will include surveys, interviews, and other relevant educational and medical documents.

NCT ID: NCT00937300 Withdrawn - Clinical trials for Head and Neck Cancer

T-cell Based Immunotherapy for Head and Neck Cancer

Start date: June 2009
Phase: Phase 1
Study type: Interventional

The aim of this study is to investigate the toxicity and immune response of therapy with tumor infiltrating lymphocytes as adjuvant treatment for head and neck cancer after primary operation and radiotherapy. Patient will receive a single treatment consisting of conditioning chemotherapy for seven days (cyclophosphamide for two days and fludarabine for five days), intravenous infusion of high number of in vitro expanded tumor infiltrating lymphocytes followed by two weeks with daily low-dose interleukine-2. Patients will be evaluated for toxicity and immune response.

NCT ID: NCT00605709 Withdrawn - Clinical trials for Squamous Cell Carcinoma

Dose-Ranging Safety and Efficacy Study of Topical Creams Containing API 31510 for the Treatment of in Situ Cutaneous Squamous Cell Carcinoma

Start date: March 2008
Phase: Phase 2
Study type: Interventional

The purpose of this study is to determine the safety and tolerability of pharmaceutical compound 31510 in a topical cream when applied to in situ cutaneous squamous cell carcinoma and to obtain preliminary efficacy data for the treatment of in situ cutaneous squamous cell carcinoma by Compound 31510 topical cream.

NCT ID: NCT00038038 Withdrawn - Clinical trials for Head and Neck Neoplasms

Assessment of Head and Neck Tumor Hypoxia Using 18F-Fluoromisonidazole

Start date: January 1994
Phase: N/A
Study type: Interventional

The purpose of this clinical research study is to answer the following questions using 18F-fluoromisonidazole as an imaging agent: 1. Do cells exist in human tumors that are at very low oxygen levels (hypoxic cells)? 2. If hypoxic cells exist in human tumors, do they effect the ability of radiotherapy to control human tumors? 3. Can Positron Emission Tomography (PET scanning) detect hypoxic cells in human tumors?